Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 8/10

vs
industry
vs
history
Cash to Debt 50.87
LMNX's Cash to Debt is ranked higher than
81% of the 308 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 1.60 vs. LMNX: 50.87 )
LMNX' s 10-Year Cash to Debt Range
Min: 3.96   Max: No Debt
Current: 50.87

Equity to Asset 0.89
LMNX's Equity to Asset is ranked higher than
95% of the 300 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 0.61 vs. LMNX: 0.89 )
LMNX' s 10-Year Equity to Asset Range
Min: 0.77   Max: 0.97
Current: 0.89

0.77
0.97
Interest Coverage 62.72
LMNX's Interest Coverage is ranked higher than
77% of the 198 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 26.96 vs. LMNX: 62.72 )
LMNX' s 10-Year Interest Coverage Range
Min: 5.66   Max: 9999.99
Current: 62.72

5.66
9999.99
F-Score: 6
Z-Score: 14.24
M-Score: -2.64
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 6/10

vs
industry
vs
history
Operating margin (%) 2.23
LMNX's Operating margin (%) is ranked higher than
65% of the 295 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 10.30 vs. LMNX: 2.23 )
LMNX' s 10-Year Operating margin (%) Range
Min: -1523.06   Max: 12.93
Current: 2.23

-1523.06
12.93
Net-margin (%) 3.32
LMNX's Net-margin (%) is ranked higher than
69% of the 295 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 8.08 vs. LMNX: 3.32 )
LMNX' s 10-Year Net-margin (%) Range
Min: -1449.74   Max: 14.7
Current: 3.32

-1449.74
14.7
ROE (%) 2.63
LMNX's ROE (%) is ranked higher than
67% of the 292 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 8.68 vs. LMNX: 2.63 )
LMNX' s 10-Year ROE (%) Range
Min: -82.88   Max: 8.11
Current: 2.63

-82.88
8.11
ROA (%) 2.32
LMNX's ROA (%) is ranked higher than
70% of the 300 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 4.50 vs. LMNX: 2.32 )
LMNX' s 10-Year ROA (%) Range
Min: -73.02   Max: 7.15
Current: 2.32

-73.02
7.15
ROC (Joel Greenblatt) (%) 6.00
LMNX's ROC (Joel Greenblatt) (%) is ranked higher than
67% of the 298 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 24.70 vs. LMNX: 6.00 )
LMNX' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -339.29   Max: 38.29
Current: 6

-339.29
38.29
Revenue Growth (%) 15.00
LMNX's Revenue Growth (%) is ranked higher than
90% of the 276 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 5.70 vs. LMNX: 15.00 )
LMNX' s 10-Year Revenue Growth (%) Range
Min: 15   Max: 191.1
Current: 15

15
191.1
EBITDA Growth (%) 9.90
LMNX's EBITDA Growth (%) is ranked higher than
80% of the 230 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 6.70 vs. LMNX: 9.90 )
LMNX' s 10-Year EBITDA Growth (%) Range
Min: -69.3   Max: 45.3
Current: 9.9

-69.3
45.3
EPS Growth (%) 12.30
LMNX's EPS Growth (%) is ranked higher than
80% of the 237 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 7.80 vs. LMNX: 12.30 )
LMNX' s 10-Year EPS Growth (%) Range
Min: -52.7   Max: 104.9
Current: 12.3

-52.7
104.9
» LMNX's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q2 2013

LMNX Guru Trades in Q2 2013

Steven Cohen 12,473 sh (New)
Joel Greenblatt 44,843 sh (New)
Jim Simons 76,140 sh (+40.12%)
PRIMECAP Management 2,566,980 sh (+3.07%)
» More
Q3 2013

LMNX Guru Trades in Q3 2013

Paul Tudor Jones 27,100 sh (New)
Steven Cohen Sold Out
PRIMECAP Management 2,526,280 sh (-1.59%)
Joel Greenblatt 37,777 sh (-15.76%)
Jim Simons 54,640 sh (-28.24%)
» More
Q4 2013

LMNX Guru Trades in Q4 2013

Jim Simons 107,140 sh (+96.08%)
Paul Tudor Jones Sold Out
Joel Greenblatt Sold Out
PRIMECAP Management 2,475,025 sh (-2.03%)
» More
Q1 2014

LMNX Guru Trades in Q1 2014

Jim Simons 111,497 sh (+4.07%)
PRIMECAP Management 2,386,259 sh (-3.59%)
» More
» Details

Insider Trades

Latest Guru Trades with LMNX

GuruDate Trades Impact to Portfolio Price Range * (?) Current Price Change from Average Current Shares
Joel Greenblatt 2013-12-31 Sold Out 0.03%$17.76 - $20.12 $ 17.72-6%0
Joel Greenblatt 2013-06-30 New Buy0.04%$15.51 - $21 $ 17.72-2%44843
Ron Baron 2012-09-30 Sold Out 0.15%$16.95 - $25.66 $ 17.72-8%0
PRIMECAP Management 2012-09-30 New Buy0.08%$16.95 - $25.66 $ 17.72-8%2495582
PRIMECAP Management 2012-06-30 Sold Out 0.09%$21.52 - $25.14 $ 17.72-25%0
Ron Baron 2011-09-30 Reduce -30%0.05%$18.5 - $24.62 $ 17.72-17%951610
Premium More recent guru trades are included for Premium Members only!!
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
P/E(ttm) 47.90
LMNX's P/E(ttm) is ranked higher than
71% of the 320 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 34.10 vs. LMNX: 47.90 )
LMNX' s 10-Year P/E(ttm) Range
Min: 29.8   Max: 646.43
Current: 47.9

29.8
646.43
P/B 2.60
LMNX's P/B is ranked higher than
76% of the 320 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 3.03 vs. LMNX: 2.60 )
LMNX' s 10-Year P/B Range
Min: 2.43   Max: 12.27
Current: 2.6

2.43
12.27
P/S 3.45
LMNX's P/S is ranked higher than
67% of the 320 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 2.91 vs. LMNX: 3.45 )
LMNX' s 10-Year P/S Range
Min: 3.14   Max: 14.45
Current: 3.45

3.14
14.45
PFCF 84.40
LMNX's PFCF is ranked higher than
76% of the 320 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 81.48 vs. LMNX: 84.40 )
LMNX' s 10-Year PFCF Range
Min: 25.16   Max: 451.73
Current: 84.4

25.16
451.73
EV-to-EBIT 44.71
LMNX's EV-to-EBIT is ranked higher than
68% of the 320 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 22.61 vs. LMNX: 44.71 )
LMNX' s 10-Year EV-to-EBIT Range
Min: 26.8   Max: 232.4
Current: 44.71

26.8
232.4
PEG 1.90
LMNX's PEG is ranked higher than
91% of the 320 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 121.00 vs. LMNX: 1.90 )
LMNX' s 10-Year PEG Range
Min: 1.78   Max: 5.38
Current: 1.9

1.78
5.38
Shiller P/E 64.10
LMNX's Shiller P/E is ranked higher than
80% of the 320 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 9999.00 vs. LMNX: 64.10 )
LMNX' s 10-Year Shiller P/E Range
Min: 57.93   Max: 386.75
Current: 64.1

57.93
386.75
Current Ratio 5.77
LMNX's Current Ratio is ranked higher than
91% of the 302 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 2.77 vs. LMNX: 5.77 )
LMNX' s 10-Year Current Ratio Range
Min: 2.39   Max: 59.71
Current: 5.77

2.39
59.71
Quick Ratio 4.59
LMNX's Quick Ratio is ranked higher than
90% of the 302 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 1.93 vs. LMNX: 4.59 )
LMNX' s 10-Year Quick Ratio Range
Min: 1.86   Max: 58.8
Current: 4.59

1.86
58.8

Valuation & Return

vs
industry
vs
history
Price/Net Cash 15.30
LMNX's Price/Net Cash is ranked higher than
90% of the 320 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 9999.00 vs. LMNX: 15.30 )
LMNX' s 10-Year Price/Net Cash Range
Min: 3.74   Max: 135.16
Current: 15.3

3.74
135.16
Price/Net Current Asset Value 8.80
LMNX's Price/Net Current Asset Value is ranked higher than
89% of the 320 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 9999.00 vs. LMNX: 8.80 )
LMNX' s 10-Year Price/Net Current Asset Value Range
Min: 3.21   Max: 116
Current: 8.8

3.21
116
Price/Tangible Book 4.40
LMNX's Price/Tangible Book is ranked higher than
75% of the 320 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 6.62 vs. LMNX: 4.40 )
LMNX' s 10-Year Price/Tangible Book Range
Min: 2.65   Max: 16.94
Current: 4.4

2.65
16.94
Price/DCF (Projected) 1.90
LMNX's Price/DCF (Projected) is ranked higher than
83% of the 320 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 5.59 vs. LMNX: 1.90 )
LMNX' s 10-Year Price/DCF (Projected) Range
Min: 1.8   Max: 11.52
Current: 1.9

1.8
11.52
Price/Median PS Value 0.50
LMNX's Price/Median PS Value is ranked higher than
95% of the 320 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 1.12 vs. LMNX: 0.50 )
LMNX' s 10-Year Price/Median PS Value Range
Min: 0.52   Max: 24.84
Current: 0.5

0.52
24.84
Price/Peter Lynch Fair Value 1.90
LMNX's Price/Peter Lynch Fair Value is ranked higher than
93% of the 320 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 9999.00 vs. LMNX: 1.90 )
LMNX' s 10-Year Price/Peter Lynch Fair Value Range
Min: 1.3   Max: 25.89
Current: 1.9

1.3
25.89
Price/Graham Number 3.00
LMNX's Price/Graham Number is ranked higher than
77% of the 320 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 5.49 vs. LMNX: 3.00 )
LMNX' s 10-Year Price/Graham Number Range
Min: 2.24   Max: 15.42
Current: 3

2.24
15.42
Earnings Yield (Greenblatt) 2.20
LMNX's Earnings Yield (Greenblatt) is ranked higher than
53% of the 252 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 5.30 vs. LMNX: 2.20 )
LMNX' s 10-Year Earnings Yield (Greenblatt) Range
Min: 0.4   Max: 3.7
Current: 2.2

0.4
3.7
Forward Rate of Return (Yacktman) 26.09
LMNX's Forward Rate of Return (Yacktman) is ranked higher than
95% of the 257 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 6.95 vs. LMNX: 26.09 )
LMNX' s 10-Year Forward Rate of Return (Yacktman) Range
Min: -0.7   Max: 32.3
Current: 26.09

-0.7
32.3

Business Description

Industry: Medical Instruments & Equipment » Medical Instruments & Supplies
Compare:WST, BAX, COV, TMO, COO » details
Traded in other countries:LMX.Germany
Luminex Corporation was incorporated under the laws of the State of Texas in May 1995, and it began commercial production of its Luminex 100 System in 1999. It was reincorporated in the State of Delaware in July 2000. The Company develops, manufactures and sells proprietary biological testing technologies and products with applications throughout the life sciences and diagnostics industries. Its xMAP (Multi-Analyte Profiling) technology, an open architecture, multiplexing technology, allows simultaneous analysis of up to 500 bioassays from a small sample volume, typically a single drop of fluid, by reading biological tests on the surface of microscopic polystyrene beads called microspheres. xMAP technology combines this miniaturized liquid array bioassay capability with small lasers, light emitting diodes (LEDs), digital signal processors, photo detectors, charge-coupled device imaging and proprietary software to create a system offering advantages in speed, precision, flexibility and cost. Its xMAP technology is currently being used within various segments of the life sciences industry, which includes the fields of drug discovery and development, and for clinical diagnostics, genetic analysis, bio-defense, food safety and biomedical research. In addition to its xMAP technology, the Company's other offerings include its proprietary MultiCode technology, used for real-time polymerase chain reaction (PCR) and multiplexed PCR assays, as well as automation and robotics in the field of dry sample handling. The Company has two reportable segments: the technology and strategic partnerships ('TSP') segment and the assays and related products ('ARP') segment. The TSP segment consists of system sales to partners and end customers, raw bead sales, royalties, service and support of the technology, and other miscellaneous items. The ARP segment is mainly involved in the development and sale of assays on xMAP and MultiCode technology for use on Luminex's installed base of systems. The TSP segment has been built around strategic partnerships. As of December 31, 2012, it had approximately 55 strategic partners, 40 of which have developed reagent-based products utilizing its technology. The Company and these partners have sold approximately 9,659 xMAP-based instruments in laboratories worldwide as of December 31, 2012. It licenses its xMAP technology to its partners, who then develop products that incorporate the xMAP technology into products that they sell to end users. The Company also develops and manufactures the proprietary xMAP laboratory instrumentation and the proprietary xMAP microspheres and sells these products to its partners. The ARP segment is mainly involved in the development and sale of assays utilizing xMAP technology on its installed base of systems. The ARP segment is mainly focused on multiplexed applications for the human molecular clinical diagnostics market. Its ARP segment products are currently focused on three segments
» More Articles for LMNX

Headlines

Articles On GuruFocus.com
BSX and ABMD Highlight Increased Insider Buying in the Medical Technology Sector May 14 2013 
Luminex Corp. (LMNX) CEO Patrick J Balthrop buys 7,000 Shares Mar 02 2010 
Luminex Corp. (LMNX) CEO Patrick J Balthrop buys 7,000 Shares Nov 16 2009 
Luminex Corporation Reports Second Quarter 2009 Results Aug 06 2009 
Luminex Corporation Reports Fourth Quarter and Year-End 2008 Results Feb 05 2009 
Luminex Corporation Fourth Quarter and Year End 2008 Earnings Release Scheduled for February 5, 2009 Jan 21 2009 

More From Other Websites
Luminex Corporation Second Quarter Earnings Release Scheduled for July 28, 2014 Jul 07 2014
Luminex Corporation Second Quarter Earnings Release Scheduled for July 28, 2014 Jul 07 2014
LUMINEX CORP Files SEC form 8-K, Submission of Matters to a Vote of Security Holders May 19 2014
LabCorp announces availability of xTAG CYP2D6 genotype assay May 19 2014
Surging Earnings Estimates Signal Good News for Luminex (LMNX) May 14 2014
Luminex Corporation Announces Group B Streptococcus (GBS), as a Launch Menu Assay for its New... May 12 2014
Luminex: 3 Different Insiders Have Sold Shares This Month May 10 2014
LUMINEX CORP Financials May 06 2014
Luminex Corporation Announces European Unveiling of its New Sample-to-Answer System at the European... May 04 2014
Luminex Corporation To Present At UBS Global Healthcare Conference May 01 2014
Why Luminex (LMNX) Stock Is Up Today Apr 29 2014
Luminex 1Q Earnings Rise 50%, Beat Ests Apr 29 2014
LUMINEX CORP Files SEC form 10-Q, Quarterly Report Apr 29 2014
Luminex Corporation's CEO Discusses Q1 2014 Results - Earnings Call Transcript Apr 28 2014
Luminex Corp Earnings Call scheduled for 5:00 pm ET today Apr 28 2014
LUMINEX CORP Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements... Apr 28 2014
Luminex Corporation Reports First Quarter 2014 Results Apr 28 2014
Q1 2014 Luminex Corp Earnings Release - After Market Close Apr 28 2014
Luminex Corporation Announces Norovirus as a Launch Menu Assay for its New Sample-to-Answer System,... Apr 22 2014
Balanced View of Luminex Corporation Apr 14 2014

Personalized Checklist








Within your circle of competence?
Macro economic environment favorable?
High quality business?
Enough margin of safety with stocks?
Gurus are buying?
Insiders are buying?
Management capable and shareholder friendly?
Catalyst for stock price to appreciate?
Your level of confidence with the research?

Add Notes, Comments or Ask Questions

User Comments

No comment yet

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
Free 7-day Trial
FEEDBACK
Email Hide